A Phase I/II Open-label, Clinical Trial of Intratumoural Ixovex-1 as Single Agent Therapy or in Combination With Pembrolizumab in Palpable Solid Tumours
Latest Information Update: 04 Feb 2025
At a glance
- Drugs Ixovex 1 (Primary) ; Pembrolizumab (Primary)
- Indications Head and neck cancer; Skin cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions
- Acronyms IXACT
- Sponsors PsiVac
Most Recent Events
- 30 Jan 2025 Status changed from not yet recruiting to recruiting.
- 21 Aug 2024 New trial record